Revolution Medicines Inc. Common Stock (RVMD) fair value

ACCE thesis

Revolution Medicines is a clinical-stage oncology company developing RAS-pathway inhibitors, the most notable being daraxonrasib (RMC-6236), a pan-RAS(ON) inhibitor aimed at tumors driven by KRAS mutations such as pancreatic cancer, where RAS has long been considered undruggable. The structural case rests on that scientific position: few competitors have a pan-RAS program advanced this far, and a validated RAS inhibitor would open a large, poorly served patient population. The near-term catalysts are the readouts and regulatory interactions from the pivotal programs, which will determine whether the platform converts into a commercial product. The data here show almost no revenue (the reported -95.2% revenue growth and a gross margin figure that is not meaningful reflect a tiny, collaboration-driven top line against heavy R&D spend), an ROE of -79.1%, and no earnings to value, so the investment case is entirely a bet on clinical and regulatory outcomes at a $41.6B market capitalization. The composite score of 36/100 and the absence of index membership reflect that risk profile, so this merits a deeper look only if the reader is prepared to underwrite binary trial outcomes.